ASX ANNOUNCEMENT

Investor Presentation - Information Session in Sydney on 2 April 2025

MELBOURNE, Australia (2 April 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to provide a copy its presentation ahead of the information session which will be held today, 2 April at 12.00pm as previously announced on 24 March 2025.

The Lumos team looks forward to seeing all those investors who can attend this information session.

-Ends-

This announcement has been approved by the Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

Lumos Diagnostics Holdings Limited

Investor Overview

2 April 2025

Financial information is shown in USD unless otherwise stated.

www.lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Company Overview and Key 1H FY25 Highlights

Who is Lumos and why do we exist?

Lumos develops, manufactures and distributes innovative diagnostic products
– delivering actionable information, in real time, at the point-of-care.

Improve the practice of medicine.

Company Overview

- Experienced leadership team
- Comprehensive & integrated offering from product concept design through to manufacture and distribution
- Developed and launched one of kind proprietary point-of-care diagnostic products - FebriDx
- Transformational development agreements with world’s leading global women’s health company – Hologic
- Currently developing proprietary women's health and sexual health point-of-care products

Lumos Business Overview

Lumos offers end-to-end point of care (POC) diagnostic test development, from initial assay creation to high-volume manufacturing. We develop and sell our own tests and also create tests for customers under commercial contracts.



Proprietary and in-licensed POC diagnostic tests and systems for commercial sale

POC diagnostic tests, digital reader formats and digital applications developed for customers under commercial contracts

Able to leverage R&D, manufacturing scale, and regulatory skillset across Lumos' Products and Commercial Services divisions

Key Highlights from 1H FY25[1]

Revenue of $6.3 million for the half-year, up 128% compared to PCP (1H FY24 - $2.8 million)

Product revenue was up 227% and Services revenue was up 118%. Gross Profit margin was a healthy 67%, an improvement of 12 percentage points over the PCP

Adjusted EBITDA loss of $0.9 million, and improvement of 77% over the loss of $4.2 million in the PCP

FebriDx - BARDA partnership in place to support CLIA waiver and paediatric studies with non-dilutive funding up to $8.3 million. CLIA Waiver study commenced in December 2024 with around 350 patients tested to-date

Cash at bank of $5.5m at 31 Dec 2024. Proforma cash of $6.4m (including BARDA payment in Jan 2025)

Work on Hologic's fFN development agreement progressing well, albeit 4 months later than planned. Phase 3 milestone payments amount to $3.7 million ($4.3m - $4.5m with expanded hardware scope of works)

1. Values in US$. Detailed 1H FY25 financials available in Appendix

Products Division

Product Portfolio Approach

Be a leader in point-of-care testing with innovative products, offering a portfolio of assays for visual read out and on a suite of differentiated, automated and connected platforms.

Focus on verticals with existing markets / reimbursement / transition from Core Lab to point-of-care / and ability to secure channel access.

Leverage broad partnering strategy for distribution and sales, secure content, share costs, and drive commercial success.

FebriDx® A Simple And Unique Test For Microbial Infection

FebriDx® can rapidly identify patients who have a microbial infection[1] and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes

Key: Markers for infection

CRP	Inflammatory marker elevated with any infection
MxA	Specific marker only elevated with viral infection

FebriDx® Test Procedure and Interpretation of Results



BACTERIAL INFECTION

Patient can be treated with antibiotics

VIRAL INFECTION

VIRAL INFECTION

Viral Infection - Antibiotics will not work
Patient needs to be managed differently

1. Microbial infection is the invasion of infectious agents into the organism, their multiplication and the reaction of host tissue against these agents. Infectious agents include bacteria, virus, parasite and fungi.

FebriDx® Addresses a major need: Antibiotic Overprescription

ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE



Acute respiratory infections may account for 58% of all antibiotics prescribed [4]

ANTIBIOTICS PRESCRIBED

211M
Antibiotic prescriptions issued in outpatient settings each year [1]

44%
Of antibiotic prescriptions are written to treat patients with aris [2]

40%
Of these are unnecessary [3]

[1] Outpatient Antibiotic Prescriptions—United States 2021: https://www.cdc.gov/antibiotic-use/data/report-2021.html
[2] Unnecessary Antibiotics for Acute Respiratory Tract Infections: Associations with Care Setting and Patient Demographics, 2016
[3] Tse, J.; Near, A. *et al*; Antibiotics 2022, 11, 1058. https://doi.org/10.3390/ antibiotics11081.
[4] Centers for Disease Control and Prevention. MMWR, 2011, 60:1153-6

Potential Benefits of FebriDx®

FebriDx® can deliver significant tangible benefits to participants across the health system

Patients

- **Reduce incidence of side effects** caused by unnecessary exposure to antibiotics
- **Objective test** result providing confidence of correct diagnosis and treatment decision
- Reduce risk of **waiting-room infection**
- Reduce **misdiagnosis** and need for subsequent follow up visits

Physicians

- Greater **confidence** on treatment decisions and need for intervention
- Reduce **risk of missing bacterial infection** in a patient
- Improve **practice workflow** allowing initial assessment conducted by practice staff
- **Reduce exposure** of staff and patients to patients with a viral infection

Insurers and Government

- Reduce antimicrobial resistance **(AMR)**
- Provide significant **cost savings**
- from reduced AMR strains
- Additional cost savings from **unnecessary deaths** and adverse **drug reactions**
- Reduces **misdiagnosis** and subsequent follow up visits

FebriDx® CLIA Waiver Update

BARDA partnership agreement | October 2024

To support CLIA waiver and pediatric studies:
non-dilutive funding up to US$8.3m

- US$3.0m to support CLIA waiver study
- US$5.3m to support pediatric study
  (children under 12yrs old)
- Payments based on achieving certain milestones

CLIA waiver clinical study commenced | December 2024

- Trial commenced on 19 December 2024 - first patient tested
- Around 350 patients tested to-date
- Bacterial prevalence lower than expected
- Implementing patient enrollment “enrichment” plan
- Anticipate completion in 2H CY2025

ViraDx™

Point-of-Care test for key respiratory infections

ViraDx highly relevant POC test for post-pandemic environment

- SARS-CoV-2 pandemic increased consumer and healthcare point-of-care testing
- ViraDx is a 3-in-1 test for COVID-19/Flu A/Flu B

ViraDx market update

Sales

- Majority of product sales during Q2 and Q3, with stocking orders received in October in preparation for the US flu season
- US flu season commenced some 6 – 8 weeks later than expected

Competition

- ViraDx has achieved new customer adoption due to the rise in infection rates - despite the US market experiencing significant competition from international organizations, with aggressive pricing

Lumos Future Products

Women's Sexual Health - $10B

Prevalence

Affects 30%-40% of women globally.
>10M heath care visits annually in the US.



Clinical Need

Multiple infectious organisms.
Similar symptoms / hard to diagnose.
Different treatments for each.



POC Diagnostic Need

Rapid & accurate testing on site needed.
Identify & treat at first patient visit.
Easy to use & trusted by clinic staff.

Women's Sexual Health – Current Diagnostic Practices

IN CLINIC TESTING

Physical Exam



Microscopic Exam

Pathogen Testing

EXTERNAL LAB TESTING

Pathogen Testing

Current Practice



Physical exam alone is not sufficient for diagnosis.

Sample collection for further analysis required.



Microscopy assists in identifying potential cause.

Pathogen testing is also run to confirm diagnosis and treatment.





Pathogen Testing today requires expensive instrumentation and skilled staff, which is a barrier for adoption.

Reimbursement is available, however insurers often reject claims due to the high cost.

Women's Sexual Health – The Opportunity

IN CLINIC TESTING

Physical Exam



Microscopic Exam

Pathogen Testing

EXTERNAL LAB TESTING

Pathogen Testing

Current Practice









Lumos Women's Sexual Health POC tests will be run by existing staff, cost effective and provide rapid and accurate results.

Reimbursement codes are available today.

Majority of clinics do not have in house testing of sexual health pathogens, due to test complexity, overheads and cost.

Instead, clinics send out testing to external labs, delaying patient diagnosis and treatment.

Lumos Product Roadmap | Women's Sexual Health

GYN CLINIC & URGENT CARE

CURRENT - DISTRIBUTION
Revenue & Market Learning

FUTURE - LUMOS POC PRODUCTS
Pathogen Detection | Visual & Reader Interpretation

Lumos – As a Distributer

Lumos Products – Visual Read

Lumos Products on Lumos Reader

Binx io
Chlamydia & Gonorrhea

Product #3

Product #4

Product #5

Product #1

Product #2

Concept Development

Technical Feasibility

Product Development

Verification & Validation

Commercialization

Commercial Services Division

Commercial Services Capabilities

Lumos offers the full range of in-house expertise required to deliver a complete, commercially ready solution.

DEVELOPMENT & MANUFACTURING

PLATFORM TECHNOLOGIES

ASSAY

READERS

EMR & CONNECTIVITIY

How we add value to partners

We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market.



Hologic - Strategic Partnership

Fetal Fibronectin (fFN)[1]

Historic relationship with Lumos <> Hologic – working together at multiple levels

- Two agreements signed in FY24 for the development of an improved version of one of Hologic's leading in-market women's health products, **Fetal Fibronectin (fFN)**, including adapting it for use on Lumos' proprietary reader platform
  - **IP Agreement** - US$10.0m - exclusive license to the Lumos proprietary reader and POC technologies for next generation fFN product - **received**
  - **Development Agreement** - up to US$5.5m over an estimated 24-month period for following milestones:
    - **Phase 1: Product Definition and Planning** - US$0.4m - **completed**
    - **Phase 2: Assay Feasibility** - US$0.6m – milestone 1 **completed** /milestone 2 **in-progress**
    - **Phase 3: System Prototype Delivery** – US$3.7m – 6 milestones – **commenced**
    - **Expanded scope of work** – announced Mar 2025 - US$0.6 - 0.8m for delivery of new hardware features - **commenced**
- **Expected Development Agreement completion by Dec 2025**

fFN is a biomarker indicating a heightened risk of pre-term delivery and is the largest segment of the pre-term birth diagnostic kit market



[1]ASX announcements 11 January 2024, 15 January 2024, 16 January 2024, 6 May 2024, 4 June 2024, 19 June 2024. 3 March 2025 2. Global Market Insights, www.gminsights.com

Hologic - fFN Product development overview and opportunity

Current test:
Rapid fFN TLiQ



Next generation test concept (mock-up)

Hologic – the opportunity ahead

- Verification and validation
- Clinical study
- Manufacturing
- Second test development and IP

Key Priorities

Key Priorities



- Implement bacterial positive enrichment strategy for FebriDx CLIA waiver trial to speed up the study
- FDA pre-submission for FebriDx pediatric study in April 2025
- Continue to drive FebriDx product awareness and sales into US urgent care centers
- Deliver on Hologic fFN development milestones - milestone 2 from Phase 2 & Phase 3 milestones
- Progress to formal product development on the first Lumos branded women's health diagnostics test

Appendix – Other Information

Board of Directors

Sam Lanyon
Non-Executive Chair

Bronwyn Le Grice
Non-Executive Director

Lawrence Mehren
Non-Executive Director

Catherine Robson
Non-Executive Director

Doug Ward
Managing Director & CEO

Highly Experienced Leadership Team

Doug Ward

CEO & Managing Director

Doug Ward has more than 30 years of biotech and medical technology experience at notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic.

With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.

Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.

Barrie Lambert

Chief Financial Officer

Barrie Lambert has more than 25 years of international experience in high growth companies from the medical device research and development services and manufacturing sector, as well other sectors. Prior to joining Lumos Diagnostics, he was CFO of Planet Innovation, one of the founding shareholders of Lumos.

Mr. Lambert has a broad background in governance, strategy, finance, M&A, operations, technology and sales. He holds a BA in Accounting from the University of South Australia and an MBA from University of Sydney. He is a chartered accountant and a graduate of the Australian Institute of Company Directors.

Sacha Dopheide, PhD

Chief Technology Officer

Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She has held an executive leadership role within Lumos Diagnostics since its 2017 acquisition of Kestrel Bioscience.

Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. She holds a BSc with First Class Honours in Biochemistry and Molecular Biology from Monash University. She received her PhD in Medicine in 2000, for which she was awarded the Victoria Fellowship for Excellence in Medical Research.

Paul Kase

SVP of Commercial Operations

Paul Kase brings more than 28 years of medical sales and leadership experience in the point-of-care diagnostic testing market to Lumos Diagnostics.

Mr. Kase is a proven leader in coaching and developing best-in-class sales teams that consistently meet and exceed revenue goals. His experience also extends to overseeing customer and technical support divisions, commercial product launches, key opinion leader development, and the creation of distributor networks in the hospital and primary care markets.

Mr. Kase earned his Bachelors in Economics and English from Bucknell University.

Company Snapshot

Issued Capital	
Shares	748.5m
Options	157.4m
Market Capitalization (AUD)	
Share price[1]	A$0.023
Market value	A$17.2m
Pro-forma Cash (31 Dec 2024 – in AUD)	A$8.7m
Enterprise value	A$8.5m
Substantial shareholders	
Tenmile Ventures	19.9%
Ryder Capital	17.0%

[1]As at close on 28 March 2025

Share Price & Volume



Board and Management

Sam Lanyon	Non-Executive Chairman
Doug Ward	CEO & Managing Director
Bronwyn Le Grice	Non-Executive Director
Lawrence Mehren	Non-Executive Director
Catherine Robson	Non-Executive Director
Barrie Lambert	CFO

Profit & Loss Summary – 1H FY25

Strong revenue growth and EBITDA improvement

Six months ended 31 Dec	1H FY25	1H FY24	% Change
Services revenue	5,468	2,510	+118%
Products revenue	838	256	+227%
Total Revenue	**6,306**	**2,766**	**+128%**
Gross Profit	4,239	1,523	+178%
GP Margin (%)	*67%*	*55%*	*+12ppts*
Other income	964	19	n/m
Operating expenses	6,141	5,709	+8%
Adjusted EBITDA	**(938)**	**(4,167)**	**-77%**
Depreciation & amortisation	(1,344)	(1,294)	+4%
Finance Costs	(300)	(802)	-63%
Share based payments	(222)	(150)	+48%
Income tax expense	-	-	-
Net (loss) after tax	**(2,804)**	**(6,413)**	**-56%**

(US$ in thousands)

Revenue

- Total revenue $6.3m (+128%)
- **Services revenue** $5.5m (+118%) - Positive impact from Hologic Development and IP agreements
- **Products revenue** $0.8m (+227%) - ViraDx sales in the US flu season and FebriDx US and International sales

Gross profit

- Gross profit $4.2m (+178%).
- GP margin 67% v's 55% (Hologic agreements impact)

Other Income is primarily from BARDA grant of $925K recognised, for milestone 1 & 2 (payment was received in January)

Operating Expenses

- $6.1m (+8%). Additional costs from FebriDx CLIA waiver trial, and some employee expenses (+4%)

EBITDA loss of $0.9m, an improvement of $3.2m (-77% on PCP)

Balance Sheet Summary – 1H FY25

Improved net asset position

Period ending	31 Dec 2024	30 Jun 2024	+/-
Assets			
Cash	5,532	6,479	-947
Inventories	1,346	784	+562
Trade & other receivables	1,639	672	+967
Contract assets	1,782	1,010	+772
Right of use assets	6,861	7,267	-406
Intangibles	8,414	9,685	-1,271
Other assets	920	941	-21
Total Assets	**26,494**	**26,838**	**-344**
Liabilities			
Trade & other payables	2,558	2,389	+169
Lease liabilities	7,807	8,060	-253
Employee benefits	1,106	1,715	-609
Contract liabilities	5,233	7,565	-2,332
Total liabilities	**16,704**	**19,729**	**-3,025**
Net Assets	**9,790**	**7,109**	**+2,681**

(US$ in thousands)

- **Inventory mainly** raw materials for ViraDx ahead of US flu season
- **Trade & Other Receivables** includes BARDA receivable of $0.9m
- **Contract Assets** primarily accrued income (timing of accrual milestone payments) on Hologic development agreement
- **Intangibles** consists of readers, FebriDx IP and Other items (reduction due to amortization and FX movement on AUD)
- **Employee Benefits** impacted by timing of payroll and vacation
- **Contract Liabilities** deposits and pre-payments by customers, mainly Hologic IP agreement.
- **Net Assets** includes capital raise during the 1H FY25

Cashflow Summary – 1H FY25

Closing cash $5.5m - well supported capital raise

Six months ended 31 Dec	1H FY25	1H FY24	+/-
Receipts from customers	3,009	2,438	+571
Payments to suppliers & employees	(9,158)	(7,401)	-1,757
Proceeds from grants	94	471	-377
Net interest received / (paid)	(261)	(349)	+88
Cash used in operating activities	**(6,316)**	**(4,841)**	**-1,475**
Payments for PP&E	(17)	(9)	-8
Capitalised product development	-	(9)	+9
Investing activities	**(17)**	**(18)**	**+1**
Proceeds from issue of shares (net of costs)	6,222	4,999	+1,223
Redemption of convertible notes	-	(1,110)	+1,110
Lease payments	(438)	(679)	+241
Financing activities	**5,784**	**3,210**	**+2,574**
Net decrease in cash	**(549)**	**(1,649)**	**+1,100**
Opening cash	6,479	3,015	+3,464
Effects of FX movement on cash	(398)	13	-411
Closing cash	**5,532**	**1,379**	**+4,153**

(US$ in thousands)

- **Receipts from customers** at $3.0m, is lower than revenue reported mainly due to recognising revenue on Hologic IP agreement (cash received in FY24) and accrued revenue on Hologic development agreement (monthly accrual v's cash received on milestone achievement)
- **Payments to suppliers & employees** at $9.2m, increased by $1.8m, 24%, from the PCP. Main movements are FebriDx CLIA waiver trial costs and working capital (mostly inventory increase for flu season)
- **Cash burn total cash** usage for the HY is $6.8m v's $5.5m in prior HY (operating + investing + lease payments). Increase due to expenses on FebriDx CLIA waiver trial costs (where costs are refunded in arrears by BARDA) and additional inventory.
- **Capital raise** in Sept 2024 - $6.2m (net of costs)
- **FX movement** on AUD held was negative $0.4m
- **Closing cash** as at 31 December 2024 of $5.5m (pro-forma $6.4m including $0.9m from BARDA collected in January 2025)

LUMOS
DIAGNOSTICS

www.lumosdiagnostics.com